As such, he is both on-topic and relevant, especially in

New Post Public Reply Private Reply Replies (3) Message Board
Bsav88atty
Quote:
As such, he is both on-topic and relevant, especially in light of the destruction to the sp that their core of fellow "investor relations related consultants" have wrought onto shareholders.


Once again, your viscous, willful, and malicious allegations of criminal acts by the "public figures" are wrong. And the same goes for your completely misguided and legally incorrect interpretations of the SEC rules. Moreover, based on SCRC's recent 8K and available public court filings, the company has strong evidence that you are dead wrong about the root cause of the "destruction to the sp." Instead, SCRC's has alleged and attached clear and convincing evidence that Ironridge was the true "destroyer" of the sp. (Tangentially, "destruction to the sp" is not a term that I would use, though it was clearly heavily manipulated. That said, the sp has found a nice base range over the past few months; it is poised to breakout. Indeed, in my strong opinion, after a couple quarters of accelerated eps growth, the sp will be significantly higher.) Back to the point: It is clear to anyone reading publicly-available Complaint that evidence exists to prove that IR's fraudulent and manipulative tactics over a several-month period was the major catalyst for the unrelenting selling pressure.

I will not restate verbatim the company's announcement of its lawsuit against IR, but here is the link to the official 8K on this issue: http://www.sec.gov/Archives/edgar/data/152147...ica_8k.htm.

I found the Complaint to which this 8K refers on Pacer. Anyone with a private Pacer account can find the Complaint, docket sheet, and other procedural docs here: UNITED STATES DISTRICT COURT for the CENTRAL DISTRICT OF CALIFORNIA (Western Division − Los Angeles) CIVIL DOCKET FOR CASE #: 2:14−cv−03962−MMM−AGR. I believe the terms and conditions of the Pacer agreement prevent me from attaching the Complaint, so I have tried to paraphrase and capture most of the important language and issues below. But again, I have not repeated each of the allegations verbatim here.

On May 22, 21014, Scrips alleged as follows against IR: (1) securities fraud under Section 10(b) of the Securities Exchange Act and Rule 10b-5, (2) breach of contract, and (3) tortious bad faith. Scrips is seeking the following relief from the court: (a) a declaratory judgment from the court that would excuse it from issuing any more shares under California state court's Stipulation, (b) compensatory damages, (c) attorneys’ fees and court costs, and (d) punitive damages.

In para #11 of the Complaint, Scrips presents a set of discussions between it and IR between August 28, 2013 and October 2, 2013 about the details of an arrangement whereby IR would pay off about $700K in SCRC payables in exchange for common shares that never had to be registered.

Per para #12, the parties discussed the mechanism that would enable IR to obtain additional shares in the event the sp declined over a defined calculation period. SCRC understood there would be a "final adjustment", from which additional shares could be issued. IR, however, failed to disclose its intent to reduce the sp through their own market manipulation to increase the number of shares at SCRC's expense. In a nutshell, IR "acted knowingly, willfully and with intent to deceive [Scrips]."

Para #13 introduces the "Term Sheet", which IR presented to Scrips on September 27, 2013 to generally outline IR's proposed transaction. (Term Sheet was attached as Ex. 1.)

Para #14 contains legal jargon required to pierce certain perceived corporate protections that were designed to protect IR and its officers and agents, specifically, John Kirkland and Brendan O'Neill from liability stemming from IR's wrongful conduct.

Para #15 describes a conversation with Kirkland and O'Neill (K&0) on October 4, 2013 in which Scrips appeared to have voiced specific concerns over the potential negative effects that IR's sale of delivered shares could have on the sp. K&O apparently assured Scrips that IR would take no action to manipulate the sp and that any sale required to pay certain "receivables would be made in such a way that they would never be more than ten percent of the volume of sales on any given day."

Per para #16 Scrips agreed to the arrangement based on all of the above-alleged "deceptive representations and fraudulent omissions." Thus, the parties agreed to a Stipulation signed by all the parties in early November covering the arrangement, which a state court judge in Las Angeles, CA approved on November 8, 2013. On the same day, Scrips issued 8,690,000 shares to IR.

Para #17 alleges IR's scheme to defraud and manipulate included a "bait and switch". "While the Term Sheet contemplated only one potential "final adjustment" that may have provided additional shares to [IR], the Stipulation included language (at para #s 7, 8, and 10) which [IR] would later contend allowed IR multiple opportunities to seek additional shares of [SCRC's] stock."

Para #18: "It was a part of the scheme to defraud and manipulate that, contrary to its repeated commitments to [Scrips], [IR] entered into a scheme of selling [Scrips's] stock with the intent of artificially lowering the price of the security, and not for any legitimate economic reason."

Para #19: "...[IR] repeatedly sold [Scrips's] stock in a volume exceeding 10% of all sales on many days." Scrips attached a chart as Ex. #3, which demonstrated IR's sales represented over 28% of the volume during the week of January 6, 2014, about 23% of the volume the week of January 21, between 30% to 50% of the volume throughout February 2014, and a high of 57% of the volume during the week of April 7, 2014!

Para #20: Part of IR's "scheme to defraud and manipulate...intent to reduce stock price for purpose of increasing the number of shares received by [IR]. [IR's] sales had a tendency and effect of reducing the price of [SCRC's] stock."

Para #21: "[IR]...deliberately intended that its sales would send false information as to the supply and demand into the market, thus inducing other sales by the general public at reduced prices, creating further market distortion...and ultimately increasing the number of shares [to IR]...[IR] is guilty of manipulative conduct, i.e., knowing and willful conduct designed to deceive or defraud investors by artificially affecting the price of a publicly-traded security.

Para #22: While the sp declined and Scrips tried to speak with IR representatives about the decline, IR "refused to answer the questions, stating that the subject was confidential."

Para #23: "[IR] successfully reduced the market price of [Scrips], which had been in the range of $.15 on the day of delivery of the stock to the range of $.10 and below in April 2014. "There was no economic basis for this reduction...Absent illegal manipulation, [SCRC's] stock price should have risen given myriad positive business developments for [Scrips]."

Para #24: IR intended to increase the number of shares through manipulation, then profit rose back to its natural level, "as justified by the economic reality of the company's performance."

Para #25: IR initially represented it intended to receive about 8.7 million shares, but then increased that demand to 12 million shares. By "invoking the so-called 'adjustment' mechanism, [IR] has already received 10.3 million of these shares, and is seeking a further 1.6 million shares through California courts, and has indicated it will seek even more in the future."

Per para #26, IR sold far more SCRC shares than was necessary to pay Scrips receivables. Indeed, Scrips alleged that IR's sales of 10,305,555 SCRC shares led to proceeds of at least $1.2 million.

Per para #28, Scrips gave IR stock valued at about $1.4 million in exchange for less than $770,000 in debt.

Per para #30, IR's actions here is merely "a part of a wider pattern of illegal and deceptive activity." Scrips cited "Scam Informer" as a resource to discover additional examples of IR's illegal and deceptive conduct.

In para #31, Scrips refers to a specific example in which IR demanded over 6 billion shares from Green Automotive Company, Inc. based on the same type of Stipulation from another California state court.

Para #s 41-42 contain the breach of contract allegations, which included breaches of para #14 of the Stipulation and the "No Shorting" provision contained on page 2 of the Term Sheet.

Para #s 43-44 contain the tortious bad faith allegations, which are based on California's covenant of good faith and fair dealing.

Para #s 45-46 address the declaratory relief (i.e., that Scrips is excused from issuing additional shares to IR).

If anyone is interested in following this litigation in real time, I recommend signing up for a Pacer account (just Google "Pacer account" to find the site). If you use Pacer to follow only the SCRC-IR litigation, it will probably be free or cost no more than $50 per quarter.

Based on my initial review and analysis of the Compliant and its attached exhibits, I believe it was well pled and sufficient to survive an initial Rule 12(b)(6) motion to dismiss, which I fully expect to be filed at the same time as IR's Answer. I also believe that considering only the evidence attached to the Complaint, Scrips has already presented sufficient admissible evidence to create at least one issue of material fact one at least one of its pleaded causes of action and, thus, Scrips will likely survive a Rule 56 motion for summary judgment. In layman's terms, I believe Scrips has a good shot at reaching trial.

So back to my original point that the tracks to the true "destroyers" of the sp do NOT lead to "the core" and the wrongly accused violators of SEC regs. On the contrary, as well-stated by Scrips's outside counsel, the tracks lead directly to Ironridge. As alleged by Scrips, for example, IR's sales of SCRC shares accounted for up to 50% of the trading volume throughout February. For a quick painful reminder of what happened to the sp during February, take a look at the chart, which depicts about a 57% drop in the sp from a high of about $.21 on or about February 1 to a dip to about $.09 on or about February 28.

Any opinions that the core, alleged "criminals" or the issuance of PIPE shares caused the "destruction" the sp have zero merit and are willfully intended to discredit and harm the reputation of honest and good people, as well as to manipulate the sp, "thus inducing other sales by the general public at reduced prices, creating further market distortion." (Incidentally, the highly destructive PIPE shares that were the worst financing deal in the history of man according to CHP, were first announced when the 10K was filed on April 15, 2014. This was long after the "destruction" to the sp. Indeed, this was during the same period we are in today in which the sp range has continued in its very long base range between about $.10 and $.12.

I typed this in a hurry and so, please excuse any typos and poor grammar.

Have a great week!

Bsav88atty (I was not compensated for posting my opinions here, nor have I ever been compensated for posting my opinions on Scrips or any other company.)

ScripsAmerica Inc (SCRC) Stock Research Links

SCRC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 7

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 5

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 3

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 5

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 2

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 3

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 4

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Shell plc: Recent Share Transactions by Management Team

Updated Category News Views 110

Shell plc made some serious moves back in September 2024 that had traders scratching their heads and looking for the fine print. They let loose a slew of notifications about share transactions by its Persons Discharging Managerial Responsibilities (PDMRs), making waves in the market. This isn’t just corporate fluff; it’s a playbook for transparency and compliance that...

Continue Reading
zSpace Faces Class Action Over IPO Missteps: Key Probe

Updated Category News Views 5

Unpacking the Explosive Allegations Against zSpace You think you're safe diving into augmented reality stocks, and then a bombshell lands. zSpace, Inc. (NASDAQ:ZSPC), a supposed leader in AR and VR educational tech, finds itself in the swirling midst of a class action lawsuit. Investors are rattled, and they're not just buzzing because their portfolios took a hit. There's...

Continue Reading
Transforming Spending: WisdomTree's Innovative Feature Launch

Updated Category News Views 164

WisdomTree Introduces Earn-Until-You-Spend Feature WisdomTree, Inc. (NYSE: WT), a leader in financial innovation, has recently announced a significant enhancement to its user experience with the introduction of a new feature allowing customers to utilize their accrued interest from the WisdomTree Government Money Market Digital Fund (WTGXX) as a funding source for the...

Continue Reading
AVITA Medical Set to Share Third Quarter 2025 Results Soon

Updated Category News Views 163

AVITA Medical to Report Financial Results AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a prominent company in therapeutic acute wound care, has made headlines with its upcoming financial disclosure. The firm is set to unveil its third-quarter financial results for 2025 after the U.S. markets close on the scheduled date. This announcement is anticipated by investors who...

Continue Reading
Hyperscale Data Celebrates Sustainable Growth with Dividends

Updated Category News Views 45

Hyperscale Data's Commendable Dividend Achievement LAS VEGAS — Hyperscale Data, Inc. (NYSE: GPUS) proudly announced it has consistently paid cash dividends for twenty-eight consecutive months on its Series D Preferred Stock. This dividend, amounting to 13.00% annually, equates to approximately $0.2708 for each share, paid monthly. This remarkable track record...

Continue Reading